Skip to main content

Advertisement

SpringerLink
Log in

Society of Surgical Oncology Breast Disease Working Group Statement on Prophylactic (Risk-Reducing) Mastectomy

  • Breast Oncology
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Over the past several years, there has been an increasing rate of bilateral prophylactic mastectomy (BPM) and contralateral prophylactic mastectomy (CPM) surgeries. Since publication of the 2007 SSO position statement on the use of risk-reducing mastectomy, there have been significant advances in the understanding of breast cancer biology and treatment. The purpose of this manuscript is to review the current literature as a resource to facilitate a shared and informed decision-making process regarding the use of risk-reducing mastectomy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Toriola AT, Colditz GA. Trends in breast cancer incidence and mortality in the United States: implications for prevention. Breast Cancer Res Treat. 2013;138(3):665–73.

    Article  PubMed  Google Scholar 

  2. Tuttle TM, Abbott A, Arrington A, Rueth N. The increasing use of prophylactic mastectomy in the prevention of breast cancer. Curr Oncol Rep. 2010;12(1):16–21.

    Article  PubMed  Google Scholar 

  3. Montgomery LL, Tran KN, Heelan MC, et al. Issues of regret in women with contralateral prophylactic mastectomies. Ann Surg Oncol. 1999;6(6):546–52.

    Article  CAS  PubMed  Google Scholar 

  4. Arrington AK, Jarosek SL, Virnig BA, Habermann EB, Tuttle TM. Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer. Ann Surg Oncol. 2009;16(10):2697–704.

    Article  PubMed  Google Scholar 

  5. King TA, Sakr R, Patil S, et al. Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol. 2011;29(16):2158–64.

    Article  PubMed  Google Scholar 

  6. Meiser B, Butow P, Friedlander M, et al. Intention to undergo prophylactic bilateral mastectomy in women at increased risk of developing hereditary breast cancer. J Clin Oncol. 2000;18(11):2250–7.

    CAS  PubMed  Google Scholar 

  7. Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families: The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62:676–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in series unselected for family history: A combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302:643–646.

    Article  CAS  PubMed  Google Scholar 

  10. Malkin D. Li-fraumeni syndrome. Genes Cancer. 2011;2(4):475–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012;18(2):400–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Casadei S, Norquist BM, Walsh T, et al. Contribution of Inherited Mutations in the BRCA2-Interacting Protein PALB2 to Familial Breast Cancer. Cancer Res. 2011;71(6):2222–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Antoniou AC, Foulkes WD, Tischkowitz M. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371(17):1651–2.

    PubMed  Google Scholar 

  14. Osorio A, Endt D, Fernandez F, et al. Predominance of pathogenic missense variants in the RAD51C gene occurring in breast and ovarian cancer families. Hum Mole Genet. 2012;21(13):2889–98.

    Article  CAS  Google Scholar 

  15. Schrader KA, Masciari S, Boyd N, et al. Hereditary diffuse gastric cancer: association with lobular breast cancer. Fam Cancer. 2008;7(1):73–82.

    Article  PubMed  Google Scholar 

  16. Hearle N, Schumacher V, Menko FH, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res. 2006;12(10):3209–15.

    Article  CAS  PubMed  Google Scholar 

  17. Weischer M, Bojesen SE, Tybjaerg-Hansen A, Axelsson CK, Nordestgaard BG. Increased risk of breast cancer associated with CHEK2*1100delC. J Clin Oncol. 2007;25(1):57–63.

    Article  CAS  PubMed  Google Scholar 

  18. de Snoo FA, Bishop DT, Bergman W, et al. Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families. Clin Cancer Res. 2008;14(21):7151–7.

    Article  PubMed  Google Scholar 

  19. Thompson ER, Rowley SM, Li N, et al. Panel testing for familial breast cancer: calibrating the tension between research and clinical care. J Clin Oncol. 2016;34(13):1455–9.

    Article  PubMed  Google Scholar 

  20. Pharoah PD, Antoniou AC, Easton DF, Ponder BA. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med. 2008;358(26):2796–803.

    Article  CAS  PubMed  Google Scholar 

  21. Reiner AS, John EM, Brooks JD, et al. Risk of asynchronous contralateral breast cancer in noncarriers of BRCA1 and BRCA2 mutations with a family history of breast cancer: a report from the Women’s Environmental Cancer and Radiation Epidemiology Study. J Clin Oncol. 2013;31(4):433–9.

    Article  PubMed  Google Scholar 

  22. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med. 1985;312(3):146–51.

    Article  CAS  PubMed  Google Scholar 

  23. Degnim AC, Visscher DW, Berman HK, et al. Stratification of breast cancer risk in women with atypia: a Mayo cohort study. J Clin Oncol. 2007;25(19):2671–7.

    Article  PubMed  Google Scholar 

  24. Coopey SB, Mazzola E, Buckley JM, et al. The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions. Breast Cancer Res Treat. 2012;136(3):627–33.

    Article  CAS  PubMed  Google Scholar 

  25. Moskowitz CS, Chou JF, Wolden SL, et al. Breast cancer after chest radiation therapy for childhood cancer. J Clin Oncol. 2014;32(21):2217–23.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Henderson TO, Amsterdam A, Bhatia S, et al. Systematic review: surveillance for breast cancer in women treated with chest radiation for childhood, adolescent, or young adult cancer. Ann Intern Med. 2010;152(7):444–55; W144–454.

  27. Oeffinger KC, Ford JS, Moskowitz CS, et al. Breast cancer surveillance practices among women previously treated with chest radiation for a childhood cancer. JAMA. 2009;301(4):404–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Chen J, Pee D, Ayyagari R, et al. Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density. J Natl Cancer Inst. 2006;98(17):1215–26.

    Article  PubMed  Google Scholar 

  29. Gail MH. Personalized estimates of breast cancer risk in clinical practice and public health. Stat Med.2011;30(10):1090–104.

    Article  PubMed  PubMed Central  Google Scholar 

  30. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomark Prev. 2006;15(6):1159–69.

    Article  Google Scholar 

  31. Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW. Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst. 2004;96(8):621–8.

    Article  CAS  PubMed  Google Scholar 

  32. 32. Freedman M, San Martin J, O’Gorman J, et al. Digitized mammography: a clinical trial of postmenopausal women randomly assigned to receive raloxifene, estrogen, or placebo. J Natl Cancer Inst. 2001;93(1):51–6.

    Article  CAS  PubMed  Google Scholar 

  33. Sandberg ME, Li J, Hall P, et al. Change of mammographic density predicts the risk of contralateral breast cancer–a case-control study. Breast Cancer Res. 2013;15(4):R57.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. Lancet Oncol. 2012;13(11):1141–51.

  35. Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E. Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst. 1997;89(3):227–38.

    Article  CAS  PubMed  Google Scholar 

  36. Antoniou AC, Pharoah PD, McMullan G, et al. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. Br J Cancer. 2002;86(1):76–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction. Cancer. 1994;73(3):643–51.

    CAS  PubMed  Google Scholar 

  38. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879–86.

    Article  CAS  PubMed  Google Scholar 

  39. Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23(7):1111–30.

    Article  PubMed  Google Scholar 

  40. CancerGene. http://www4.utsouthwestern.edu/breasthealth/cagene/. Accessed 28 Nov 2016.

  41. Hughes Risk Apps. http://www.crahealth.com/. Accessed 28 Nov 2016.

  42. Institute NC. Breast cancer risk prediction models. http://epi.grants.cancer.gov/cancer_risk_prediction/breast.html. Accessed 28 Nov 2016.

  43. Pankratz VS, Hartmann LC, Degnim AC, et al. Assessment of the accuracy of the Gail model in women with atypical hyperplasia. J Clin Oncol. 2008;26(33):5374–9.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Boughey JC, Hartmann LC, Anderson SS, et al. Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia. J Clin Oncol. 2010;28(22):3591–6.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Panchal S, Bordeleau L, Poll A, et al. Does family history predict the age at onset of new breast cancers in BRCA1 and BRCA2 mutation-positive families? Clin Genet. 2010;77(3):273–9.

    Article  CAS  PubMed  Google Scholar 

  46. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250(4985):1233–8.

    Article  CAS  PubMed  Google Scholar 

  47. Meijers-Heijboer H, van den Ouweland A, Klijn J, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nature Genet. 2002;31(1):55–9.

    Article  CAS  PubMed  Google Scholar 

  48. Horvath A, Pakala SB, Mudvari P, et al. Novel insights into breast cancer genetic variance through RNA sequencing. Sci Rep. 2013;3:2256.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Kurian AW, Munoz DF, Rust P, et al. Online tool to guide decisions for BRCA1/2 mutation carriers. J Clin Oncol. 2012;30(5):497–506.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Evans DG, Lalloo F, Ashcroft L, et al. Uptake of risk-reducing surgery in unaffected women at high risk of breast and ovarian cancer is risk, age, and time dependent. Cancer Epidemiol Biomark Prev. 2009;18(8):2318–24.

    Article  Google Scholar 

  51. Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, et al. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet. 2000;355(9220):2015–20.

    Article  CAS  PubMed  Google Scholar 

  52. Bebbington Hatcher M, Fallowfield LJ. A qualitative study looking at the psychosocial implications of bilateral prophylactic mastectomy. Breast. 2003;12(1):1–9.

    Article  CAS  PubMed  Google Scholar 

  53. Metcalfe KA, Foulkes WD, Kim-Sing C, et al. Family history as a predictor of uptake of cancer preventive procedures by women with a BRCA1 or BRCA2 mutation. Clin Genet. 2008;73(5):474–9.

    Article  CAS  PubMed  Google Scholar 

  54. Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. 2010;(11):CD002748.

  55. Meijers-Heijboer H, van Geel B, van Putten WL, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345(3):159–64.

    Article  CAS  PubMed  Google Scholar 

  56. Rebbeck TR, Friebel T, Lynch HT, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004;22(6):1055–62.

    Article  PubMed  Google Scholar 

  57. Skytte AB, Cruger D, Gerster M, et al. Breast cancer after bilateral risk-reducing mastectomy. Clin Genet. 2011;79(5):431–37.

    Article  PubMed  Google Scholar 

  58. Domchek SM, Friebel TM, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340(2):77–84.

    Article  CAS  PubMed  Google Scholar 

  60. Geiger AM, Yu O, Herrinton LJ, et al. A population-based study of bilateral prophylactic mastectomy efficacy in women at elevated risk for breast cancer in community practices. Arch Intern Med. 2005;165(5):516–20.

    Article  PubMed  Google Scholar 

  61. Kaas R, Kroger R, Hendriks JH, et al. The significance of circumscribed malignant mammographic masses in the surveillance of BRCA 1/2 gene mutation carriers. Eur Radiol. 2004;14(9):1647–53.

    Article  CAS  PubMed  Google Scholar 

  62. Contant CM, Menke-Pluijmers MB, Seynaeve C, et al. Clinical experience of prophylactic mastectomy followed by immediate breast reconstruction in women at hereditary risk of breast cancer (HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation. Eur J Surg Oncol. 2002;28(6):627–32.

    Article  CAS  PubMed  Google Scholar 

  63. Heemskerk-Gerritsen BA, Brekelmans CT, Menke-Pluymers MB, et al. Prophylactic mastectomy in BRCA1/2 mutation carriers and women at risk of hereditary breast cancer: long-term experiences at the Rotterdam Family Cancer Clinic. Ann Surg Oncol. 2007;14(12):3335–44.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Arver B, Isaksson K, Atterhem H, et al. Bilateral prophylactic mastectomy in Swedish women at high risk of breast cancer: a national survey. Ann Surg. 2011;253(6):1147–54.

    Article  PubMed  Google Scholar 

  65. Evans DG, Baildam AD, Anderson E, et al. Risk reducing mastectomy: outcomes in 10 European centres. J Med Genet. 2009;46(4):254–8.

    Article  CAS  PubMed  Google Scholar 

  66. Kurian AW, Sigal BM, Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol. 2010;28(2):222–231.

    Article  CAS  PubMed  Google Scholar 

  67. Sigal BM, Munoz DF, Kurian AW, Plevritis SK. A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomark Prev. 2012;21(7):1066–77.

    Article  CAS  Google Scholar 

  68. Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22(12):2328–35.

    Article  CAS  PubMed  Google Scholar 

  69. Herrinton LJ, Barlow WE, Yu O, et al. Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol. 2005;23(19):4275–86.

    Article  PubMed  Google Scholar 

  70. van Sprundel TC, Schmidt MK, Rookus MA, et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer. 2005;93(3):287–92.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  71. McDonnell SK, Schaid DJ, Myers JL, et al. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. J Clin Oncol. 2001;19(19):3938–43.

    CAS  PubMed  Google Scholar 

  72. Goldflam K, Hunt KK, Gershenwald JE, et al. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer. 2004;101(9):1977–86.

    PubMed  Google Scholar 

  73. Peralta EA, Ellenhorn JD, Wagman LD, Dagis A, Andersen JS, Chu DZ. Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg. 2000;180(6):439–45.

    Article  CAS  PubMed  Google Scholar 

  74. Boughey JC, Hoskin TL, Degnim AC, et al. Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol. 2010;17(10):2702–9.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Chung A, Huynh K, Lawrence C, Sim MS, Giuliano A. Comparison of patient characteristics and outcomes of contralateral prophylactic mastectomy and unilateral total mastectomy in breast cancer patients. Ann Surg Oncol. 2012;19(8):2600–6.

    Article  PubMed  Google Scholar 

  76. Brewster AM, Bedrosian I, Parker PA, et al. Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status. Cancer. 2012;118(22):5637–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Bedrosian I, Hu CY, Chang GJ. Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst. 2010;102(6):401–09.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Lee JS, Grant CS, Donohue JH, Crotty TB, Harmsen WS, Ilstrup DM. Arguments against routine contralateral mastectomy or undirected biopsy for invasive lobular breast cancer. Surgery. 1995;118(4):640–7; discussion 647–648.

  79. Brekelmans CT, Seynaeve C, Menke-Pluymers M, et al. Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol. 2006;17(3):391–400.

    Article  CAS  PubMed  Google Scholar 

  80. Brekelmans CT, Tilanus-Linthorst MM, Seynaeve C, et al. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases. Eur J Cancer. 2007;43(5):867–76.

    Article  CAS  PubMed  Google Scholar 

  81. Babiera GV, Lowy AM, Davidson SB, Singletary SE. The role of contralateral prophylactic mastectomy in invasive lobular carcinoma. Breast J. 1997;3:2–6.

    Article  Google Scholar 

  82. Tuttle TM, Habermann EB, Virnig B. Re: Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst. 2010;102(17):1371–2; author reply 1372–1373.

  83. Jatoi I, Parsons HM. Contralateral prophylactic mastectomy and its association with reduced mortality: evidence for selection bias. Breast Cancer Res Treat. 2014;148(2):389–96.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Narod SA. The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer. Breast Cancer Res Treat. 2011;128(2):581–3.

    Article  CAS  PubMed  Google Scholar 

  85. Portschy PR, Kuntz KM, Tuttle TM. Survival outcomes after contralateral prophylactic mastectomy: a decision analysis. J Natl Cancer Inst. 2014;106(8).

  86. Davies KR, Cantor SB, Brewster AM. Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomy. Int J Womens Health. 2015;7:181–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  87. Pesce C, Liederbach E, Wang C, Lapin B, Winchester DJ, Yao K. Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer. Ann Surg Oncol. 2014;21(10):3231–9.

    Article  PubMed  Google Scholar 

  88. Early Breast Cancer Trialists’ Collaborative Group.Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717.

  89. Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11(12):1135–41.

    Article  CAS  PubMed  Google Scholar 

  90. Nichols HB, Berrington de Gonzalez A, Lacey JV Jr, Rosenberg PS, Anderson WF. Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol. 2011;29(12):1564–9.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Robertson C, Arcot Ragupathy SK, Boachie C, et al. The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews registry database analyses and economic evaluation. Health Technol Assess. 2011;15(34):v–vi, 1–322.

  92. Yao K, Stewart AK, Winchester DJ, Winchester DP. Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the National Cancer Data Base, 1998-2007. Ann Surg Oncol. 2010;17(10):2554–62.

    Article  PubMed  Google Scholar 

  93. Güth U, Myrick ME, Viehl CT, Weber WP, Lardi AM, Schmid SM. Increasing rates of contralateral prophylactic mastectomy - a trend made in USA? Eur J Surg Oncol. 2012;38(4):296–301.

    Article  PubMed  Google Scholar 

  94. King TA, Gurevich I, Sakr R, Patil S, Stempel M, Morrow M. Occult malignancy in patients undergoing contralateral prophylactic mastectomy. Ann Surg. 2011;254(1):2–7.

    Article  PubMed  Google Scholar 

  95. Yi M, Hunt KK, Arun BK, et al. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila). 2010;3(8):1026–34.

    Article  PubMed  PubMed Central  Google Scholar 

  96. Jones NB, Wilson J, Kotur L, Stephens J, Farrar WB, Agnese DM. Contralateral prophylactic mastectomy for unilateral breast cancer: an increasing trend at a single institution. Ann Surg Oncol. 2009;16(10):2691–6.

    Article  PubMed  Google Scholar 

  97. Graves KD, Peshkin BN, Halbert CH, DeMarco TA, Isaacs C, Schwartz MD. Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors. Breast Cancer Res Treat. 2007;104(3):321–29.

    Article  PubMed  Google Scholar 

  98. Stucky CC, Gray RJ, Wasif N, Dueck AC, Pockaj BA. Increase in contralateral prophylactic mastectomy: echoes of a bygone era? Surgical trends for unilateral breast cancer. Ann Surg Oncol. 2010;17 Suppl 3:330–7.

    Article  PubMed  Google Scholar 

  99. Damle S, Teal CB, Lenert JJ, Marshall EC, Pan Q, McSwain AP. Mastectomy and contralateral prophylactic mastectomy rates: an institutional review. Ann Surg Oncol. 2011;18(5):1356–63.

    Article  PubMed  Google Scholar 

  100. Albornoz CR, Matros E, Lee CN, et al. Bilateral mastectomy versus breast-conserving surgery for early-stage breast cancer: the role of breast reconstruction. Plast Reconstr Surg. 2015;135(6):1518–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Dragun AE, Pan J, Riley EC, et al. Increasing use of elective mastectomy and contralateral prophylactic surgery among breast conservation candidates: a 14-year report from a comprehensive cancer center. Am J Clin Oncol. 2013;36(4):375–80.

    Article  PubMed  Google Scholar 

  102. Black DM, Hunt KK, Mittendorf EA. Long term outcomes reporting the safety of breast conserving therapy compared to mastectomy: 20-year results of EORTC 10801. Gland Surg. 2013;2(3):120–3.

    PubMed  PubMed Central  Google Scholar 

  103. Litiere S, Werutsky G, Fentiman IS, et al. Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol. 2012;13(4):412–9.

    Article  PubMed  Google Scholar 

  104. Crosby MA, Garvey PB, Selber JC, et al. Reconstructive outcomes in patients undergoing contralateral prophylactic mastectomy. Plast Reconstr Surg. 2011;128(5):1025–33.

    Article  CAS  PubMed  Google Scholar 

  105. Fisher CS, Martin-Dunlap T, Ruppel MB, Gao F, Atkins J, Margenthaler JA. Fear of recurrence and perceived survival benefit are primary motivators for choosing mastectomy over breast-conservation therapy regardless of age. Ann Surg Oncol. 2012;19(10):3246–50.

    Article  PubMed  Google Scholar 

  106. Abbott A, Rueth N, Pappas-Varco S, Kuntz K, Kerr E, Tuttle T. Perceptions of contralateral breast cancer: an overestimation of risk. Ann Surg Oncol. 2011;18(11):3129–36.

    Article  PubMed  Google Scholar 

  107. Kwong A, Chu AT. What made her give up her breasts: a qualitative study on decisional considerations for contralateral prophylactic mastectomy among breast cancer survivors undergoing BRCA1/2 genetic testing. Asian Pac J Cancer Prev. 2012;13(5):2241–7.

    Article  PubMed  Google Scholar 

  108. Geiger AM, West CN, Nekhlyudov L, et al. Contentment with quality of life among breast cancer survivors with and without contralateral prophylactic mastectomy. J Clin Oncol. 2006;24(9):1350–6.

    Article  PubMed  Google Scholar 

  109. McCready DR, Escallon J. Clinical considerations regarding contralateral prophylactic mastectomy. Womens Health (Lond). 2007;3(1):39–43.

    Article  PubMed  Google Scholar 

  110. Tuttle TM. Counseling breast cancer patients on contralateral prophylactic mastectomy: the physician’s role. Oncology (Williston Park). 2008;22(5):545–8.

    PubMed  Google Scholar 

  111. Wood WC. Increasing use of contralateral prophylactic mastectomy: a counterintuitive trend. Oncology (Williston Park). 2008;22(5):548–51.

    PubMed  Google Scholar 

  112. Khan SA. Contralateral prophylactic mastectomy: what do we know and what do our patients know? J Clin Oncol. 2011;29(16):2132–5.

    Article  PubMed  Google Scholar 

  113. Gopie JP, Mureau MA, Seynaeve C, et al. Body image issues after bilateral prophylactic mastectomy with breast reconstruction in healthy women at risk for hereditary breast cancer. Fam Cancer. 2013;12(3):479–87.

    Article  PubMed  Google Scholar 

  114. Gahm J, Wickman M, Brandberg Y. Bilateral prophylactic mastectomy in women with inherited risk of breast cancer: prevalence of pain and discomfort, impact on sexuality, quality of life and feelings of regret two years after surgery. Breast. 2010;19(6):462–9.

    Article  PubMed  Google Scholar 

  115. Brandberg Y, Sandelin K, Erickson S, et al. Psychological reactions, quality of life, and body image after bilateral prophylactic mastectomy in women at high risk for breast cancer: a prospective 1-year follow-up study. J Clin Oncol. 2008:26(24): 3943–9.

    Article  PubMed  Google Scholar 

  116. Unukovych D, Sandelin K, Liljegren A, et al. Contralateral prophylactic mastectomy in breast cancer patients with a family history: a prospective 2-years follow-up study of health related quality of life, sexuality and body image. Eur J Cancer. 2012;48(17):3150–6.

    Article  PubMed  Google Scholar 

  117. Frost MH, Hoskin TL, Hartmann LC, Degnim AC, Johnson JL, Boughey JC. Contralateral prophylactic mastectomy: long-term consistency of satisfaction and adverse effects and the significance of informed decision-making, quality of life, and personality traits. Ann Surg Oncol. 2011;18(11):3110–6.

    Article  PubMed  PubMed Central  Google Scholar 

  118. Altschuler A, Nekhlyudov L, Rolnick SJ, et al. Positive, negative, and disparate–women’s differing long-term psychosocial experiences of bilateral or contralateral prophylactic mastectomy. Breast J. 2008;14(1):25–32.

    Article  PubMed  Google Scholar 

  119. Frost MH, Slezak JM, Tran NV, et al. Satisfaction after contralateral prophylactic mastectomy: the significance of mastectomy type, reconstructive complications, and body appearance. J Clin Oncol. 2005;23(31):7849–56.

    Article  PubMed  Google Scholar 

  120. Hwang ES, Locklear TD, Rushing CN, et al. Patient-reported outcomes after choice for contralateral prophylactic mastectomy. J Clin Oncol. 2016;34(13):1518–27.

    Article  PubMed  Google Scholar 

  121. Roberts A, Habibi M, Frick KD. Cost-effectiveness of contralateral prophylactic mastectomy for prevention of contralateral breast cancer. Ann Surg Oncol. 2014;21(7):2209–17.

    Article  PubMed  Google Scholar 

  122. Mattos D, Gfrerer L, Reish RG, et al. Lifetime costs of prophylactic mastectomies and reconstruction versus surveillance. Plast Reconstr Surg. 2015;136(6):730e–40e.

    Article  CAS  PubMed  Google Scholar 

  123. Tokin C, Weiss A, Wang-Rodriguez J, Blair SL. Oncologic safety of skin-sparing and nipple-sparing mastectomy: a discussion and review of the literature. Int J Surg Oncol. 2012;2012:921821.

    PubMed  PubMed Central  Google Scholar 

  124. Agrawal A, Sibbering DM, Courtney CA. Skin sparing mastectomy and immediate breast reconstruction: a review. Eur J Surg Oncol. 2013;39:320–8.

  125. Boneti C, Yuen J, Santiago C, et al. Oncologic safety of nipple skin-sparing or total skin-sparing mastectomies with immediate reconstruction. J Am Coll Surg. 2011;212(4):686–693; discussion 693–685.

  126. Peled AW, Foster RD, Stover AC, et al. Outcomes after total skin-sparing mastectomy and immediate reconstruction in 657 breasts. Ann Surg Oncol.;19(11):3402–9.

  127. Murthy V, Chamberlain RS. Defining a place for nipple sparing mastectomy in modern breast care: an evidence based review. Breast J. 2013;19(6):571–81.

    Article  PubMed  Google Scholar 

  128. Lagios MD, Gates EA, Westdahl PR, Richards V, Alpert BS. A guide to the frequency of nipple involvement in breast cancer. A study of 149 consecutive mastectomies using a serial subgross and correlated radiographic technique. Am J Surg. 1979;138(1):135–42.

  129. Fisher ER, Gregorio R, Redmond C, Vellios F, Sommers SC, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol no. 4). I. Observations concerning the multicentricity of mammary cancer. Cancer. 1975;35(1):247–54.

    Article  CAS  PubMed  Google Scholar 

  130. Kissin MW, Kark AE. Nipple preservation during mastectomy. Br J Surg. 1987;74(1):58–61.

    Article  CAS  PubMed  Google Scholar 

  131. Laronga C, Kemp B, Johnston D, Robb GL, Singletary SE. The incidence of occult nipple-areola complex involvement in breast cancer patients receiving a skin-sparing mastectomy. Ann Surg Oncol. 1999;6(6):609–613.

    Article  CAS  PubMed  Google Scholar 

  132. Crowe JP Jr, Kim JA, Yetman R, Banbury J, Patrick RJ, Baynes D. Nipple-sparing mastectomy: technique and results of 54 procedures. Arch Surg. 2004;139(2):148–50.

    Article  PubMed  Google Scholar 

  133. Simmons RM, Adamovich TL. Skin-sparing mastectomy. Surg Clin North Am. 2003;83(4):885–99.

    Article  PubMed  Google Scholar 

  134. Klimberg VS, Westbrook KC, Korourian S. Use of touch preps for diagnosis and evaluation of surgical margins in breast cancer. Ann Surg Oncol. 1998;5(3):220–6.

    Article  CAS  PubMed  Google Scholar 

  135. De La Cruz L, Moody AM, Tappy EE, Blankenship SA, Hecht EM. Overall survival, disease-free survival, local recurrence, and nipple-areolar recurrence in the setting of nipple-sparing mastectomy: a meta-analysis and systematic review. Ann Surg Oncol. 2015;22(10):3241–3249.

    Article  Google Scholar 

  136. Reynolds C, Davidson JA, Lindor NM, et al. Prophylactic and therapeutic mastectomy in BRCA mutation carriers: can the nipple be preserved? Ann Surg Oncol. 2011;18(11):3102–9.

    Article  PubMed  Google Scholar 

  137. Peled AW, Irwin CS, Hwang ES, Ewing CA, Alvarado M, Esserman LJ. Total skin-sparing mastectomy in BRCA mutation carriers. Ann Surg Oncol. 2014;21(1):37–41.

    Article  PubMed  Google Scholar 

  138. van Verschuer VM, Maijers MC, van Deurzen CH, Koppert LB. Oncological safety of prophylactic breast surgery: skin-sparing and nipple-sparing versus total mastectomy. Gland Surg. 2015;4(6):467–75.

    PubMed  PubMed Central  Google Scholar 

  139. Griepsma M, de Roy van Zuidewijn DB, Grond AJ, Siesling S, Groen H, de Bock GH. Residual breast tissue after mastectomy: how often and where is it located? Ann Surg Oncol. 2014;21(4):1260–6.

    Article  CAS  PubMed  Google Scholar 

  140. Rai SS, Mahabir RC, Roberts JW, Song J, Hamid KS, White RR. Contralateral prophylactic mastectomy. Ann Plast Surg. 2011;67(3):215–9.

    Article  CAS  PubMed  Google Scholar 

  141. Yi M, Meric-Bernstam F, Middleton LP, et al. Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer. 2009;115(5):962–71.

    Article  PubMed  PubMed Central  Google Scholar 

  142. Boughey JC, Khakpour N, Meric-Bernstam F, et al. Selective use of sentinel lymph node surgery during prophylactic mastectomy. Cancer. 2006;107(7):1440–7.

    Article  PubMed  Google Scholar 

  143. Nasser SM, Smith SG, Chagpar AB. The role of sentinel node biopsy in women undergoing prophylactic mastectomy. J Surg Res. 2010;164(2):188–192.

    Article  PubMed  Google Scholar 

  144. Black D, Specht M, Lee JM, et al. Detecting occult malignancy in prophylactic mastectomy: preoperative MRI versus sentinel lymph node biopsy. Ann Surg Oncol. 2007;14(9):2477–2484.

    Article  PubMed  Google Scholar 

  145. Laronga C, Lee MC, McGuire KP, et al. Indications for sentinel lymph node biopsy in the setting of prophylactic mastectomy. J Am Coll Surg. 2009;209(6):746–752; quiz 800-741.

  146. Boughey JC, Cormier JN, Xing Y, et al. Decision analysis to assess the efficacy of routine sentinel lymphadenectomy in patients undergoing prophylactic mastectomy. Cancer. 2007;110(11):2542–50.

    Article  PubMed  Google Scholar 

  147. Czyszczon IA, Roland L, Sahoo S. Routine prophylactic sentinel lymph node biopsy is not indicated in women undergoing prophylactic mastectomy. J Surg Oncol. 2012;105(7):650–54.

    Article  PubMed  Google Scholar 

  148. Bernard JR Jr, Vallow LA, DePeri ER, et al. In newly diagnosed breast cancer, screening MRI of the contralateral breast detects mammographically occult cancer, even in elderly women: the mayo clinic in Florida experience. Breast J. 2010;16(2):118–26.

    Article  PubMed  Google Scholar 

  149. Hollingsworth AB, Stough RG. Multicentric and contralateral invasive tumors identified with pre-op MRI in patients newly diagnosed with ductal carcinoma in situ of the breast. Breast J. 2012;18(5):420–7.

    Article  PubMed  Google Scholar 

  150. Lehman CD, Gatsonis C, Kuhl CK, et al. MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med. 2007;356(13):1295–303.

    Article  CAS  PubMed  Google Scholar 

  151. Rieber A, Merkle E, Bohm W, Brambs HJ, Tomczak R. MRI of histologically confirmed mammary carcinoma: clinical relevance of diagnostic procedures for detection of multifocal or contralateral secondary carcinoma. J Comput Assist Tomogr. 1997;21(5):773–9.

    Article  CAS  PubMed  Google Scholar 

  152. McLaughlin SA, Stempel M, Morris EA, Liberman L, King TA. Can magnetic resonance imaging be used to select patients for sentinel lymph node biopsy in prophylactic mastectomy? Cancer. 2008;112(6):1214–1221.

    Article  PubMed  Google Scholar 

  153. Fox KR. The role of MRI scanning of the contralateral breast in women with newly diagnosed breast cancer: a new care standard or not? Curr Oncol Rep. 2008;10(1):8–9.

    Article  PubMed  Google Scholar 

  154. Gabriel SE, Woods JE, O’Fallon WM, Beard CM, Kurland LT, Melton LJ 3rd. Complications leading to surgery after breast implantation. N Engl J Med. 1997;336(10):677–82.

    Article  CAS  PubMed  Google Scholar 

  155. Crosby MA, Card A, Liu J, Lindstrom WA, Chang DW. Immediate breast reconstruction and lymphedema incidence. Plast Reconstr Surg. 2012;129(5):789e–95e.

    Article  PubMed  CAS  Google Scholar 

  156. Zion SM, Slezak JM, Sellers TA, et al. Reoperations after prophylactic mastectomy with or without implant reconstruction. Cancer. 2003;98(10):2152–60.

    Article  PubMed  Google Scholar 

  157. Malata CM, McIntosh SA, Purushotham AD. Immediate breast reconstruction after mastectomy for cancer. Br J Surg. 2000;87(11):1455–72.

    Article  CAS  PubMed  Google Scholar 

  158. Caffo O, Cazzolli D, Scalet A, et al. Concurrent adjuvant chemotherapy and immediate breast reconstruction with skin expanders after mastectomy for breast cancer. Breast Cancer Res Treat. 2000;60(3):267–75.

    Article  CAS  PubMed  Google Scholar 

  159. Johansen J, Overgaard J, Overgaard M. Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation. Acta Oncol. 2007;46(4):525–33.

    Article  PubMed  Google Scholar 

  160. Barton MB, West CN, Liu IL, et al. Complications following bilateral prophylactic mastectomy. J Natl Cancer Inst Monogr. 2005(35):61–66.

    Article  Google Scholar 

  161. Allweis TM, Boisvert ME, Otero SE, Perry DJ, Dubin NH, Priebat DA. Immediate reconstruction after mastectomy for breast cancer does not prolong the time to starting adjuvant chemotherapy. Am J Surg. 2002;183(3):218–21.

    Article  PubMed  Google Scholar 

  162. Mortenson MM, Schneider PD, Khatri VP, et al. Immediate breast reconstruction after mastectomy increases wound complications: however, initiation of adjuvant chemotherapy is not delayed. Arch Surg. 2004;139(9):988–91.

    Article  PubMed  Google Scholar 

  163. Wilson CR, Brown IM, Weiller-Mithoff E, George WD, Doughty JC. Immediate breast reconstruction does not lead to a delay in the delivery of adjuvant chemotherapy. Eur J Surg Oncol. 2004;30(6):624–7.

    Article  CAS  PubMed  Google Scholar 

  164. Zhong T, Hofer SO, McCready DR, Jacks LM, Cook FE, Baxter N. A comparison of surgical complications between immediate breast reconstruction and mastectomy: the impact on delivery of chemotherapy–an analysis of 391 procedures. Ann Surg Oncol. 2012;19(2):560–6.

    Article  PubMed  Google Scholar 

  165. Alderman AK, Collins ED, Schott A, et al. The impact of breast reconstruction on the delivery of chemotherapy. Cancer. 2010;116(7):1791–800.

    Article  PubMed  PubMed Central  Google Scholar 

  166. Taylor CW, Kumar S. The effect of immediate breast reconstruction on adjuvant chemotherapy. Breast. 2005;14(1):18–21.

    Article  CAS  PubMed  Google Scholar 

  167. Kronowitz SJ, Robb GL. Breast reconstruction with postmastectomy radiation therapy: current issues. Plast Reconstr Surg. 2004;114(4):950–60.

    Article  PubMed  Google Scholar 

  168. Motwani SB, Strom EA, Schechter NR, et al. The impact of immediate breast reconstruction on the technical delivery of postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66(1):76–82.

    Article  PubMed  Google Scholar 

  169. Spear SL, Onyewu C. Staged breast reconstruction with saline-filled implants in the irradiated breast: recent trends and therapeutic implications. Plast Reconstr Surg. 2000;105(3):930–42.

    Article  CAS  PubMed  Google Scholar 

  170. Tran NV, Chang DW, Gupta A, Kroll SS, Robb GL. Comparison of immediate and delayed free TRAM flap breast reconstruction in patients receiving postmastectomy radiation therapy. Plasti Reconstr Surg. 2001;108(1):78–82.

    Article  CAS  Google Scholar 

  171. Chang EI, Liu TS, Festekjian JH, Da Lio AL, Crisera CA. Effects of radiation therapy for breast cancer based on type of free flap reconstruction. Plast Reconstr Surg. 2013;131(1):1e–8e.

    Article  CAS  PubMed  Google Scholar 

  172. Chlebowski RT. Nutrition and physical activity influence on breast cancer incidence and outcome. Breast. 2013;22 Suppl 2:S30–37.

    Article  PubMed  Google Scholar 

  173. Pruthi S, Heisey RE, Bevers TB. Chemoprevention for breast cancer. Ann Surg Oncol. 2015;22(10):3230–5.

    Article  PubMed  PubMed Central  Google Scholar 

  174. Romieu I, Scoccianti C, Chajes V, et al. Alcohol intake and breast cancer in the European prospective investigation into cancer and nutrition. Int J Cancer. 2015;137(8):1921–1930.

    Article  CAS  PubMed  Google Scholar 

  175. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371–88.

    Article  CAS  PubMed  Google Scholar 

  176. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97(22):1652–62.

    Article  CAS  PubMed  Google Scholar 

  177. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet. 2002;360(9336):817–24.

    Article  CAS  PubMed  Google Scholar 

  178. Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015;16(1):67–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  179. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet. 1998;352(9122):98–101.

    Article  CAS  PubMed  Google Scholar 

  180. Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst. 2007;99(9):727–37.

    Article  CAS  PubMed  Google Scholar 

  181. Dickler MN, Norton L. The MORE trial: multiple outcomes for Raloxifene evaluation–breast cancer as a secondary end point: implications for prevention. Ann NY Acad Sci. 2001;949:134–42.

    Article  CAS  PubMed  Google Scholar 

  182. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila). 2010;3(6):696–706.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  183. Goss PE, Ingle JN, Ales-Martinez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364(25):2381–91.

    Article  CAS  PubMed  Google Scholar 

  184. Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014;383(9922):1041–8.

    Article  CAS  PubMed  Google Scholar 

  185. Chang-Claude J, Andrieu N, Rookus M, et al. Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomark Prev. 2007;16(4):740–6.

    Article  PubMed  Google Scholar 

  186. Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005;23(30):7491–6.

    Article  PubMed  Google Scholar 

  187. Finkelman BS, Rubinstein WS, Friedman S, et al. Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol. 2012;30(12):1321–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  188. Kauff ND. Is It time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer? J Clin Oncol. 2008;26(1):9–10.

    Article  PubMed  Google Scholar 

  189. Kramer JL, Velazquez IA, Chen BE, Rosenberg PS, Struewing JP, Greene MH. Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol. 2005;23(34):8629–35.

    Article  PubMed  Google Scholar 

  190. Li X, You R, Wang X, et al. Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: a meta-analysis and systematic review. Clin Cancer Res. 2016;22(15):3971–81.

    Article  CAS  PubMed  Google Scholar 

  191. Duffy SW, Tabar L, Vitak B, et al. The Swedish Two-County Trial of mammographic screening: cluster randomisation and end point evaluation. Ann Oncol. 2003;14(8):1196–8.

    Article  CAS  PubMed  Google Scholar 

  192. Berg WA, Gutierrez L, NessAiver MS, et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology. 2004;233(3):830–49.

    Article  PubMed  Google Scholar 

  193. Gradishar WJ, Anderson BO, Blair SL, et al. Breast cancer version 3.2014. J Natl Compr Cancer Netw. 2014;12(4):542–90.

    CAS  Google Scholar 

  194. Wuttke M, Phillips KA. Clinical management of women at high risk of breast cancer. Curr Opin Obstet Gynecol. 2015;27(1):6–13.

    Article  PubMed  Google Scholar 

  195. Le-Petross HT, Whitman GJ, Atchley DP, et al. Effectiveness of alternating mammography and magnetic resonance imaging for screening women with deleterious BRCA mutations at high risk of breast cancer. Cancer. 2011;117(17):3900–7.

    Article  PubMed  Google Scholar 

  196. Warner E, Plewes DB, Hill KA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004;292(11):1317–25.

    Article  CAS  PubMed  Google Scholar 

  197. Kriege M, Brekelmans CT, Boetes C, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004;351(5):427–37.

    Article  CAS  PubMed  Google Scholar 

  198. Lehman CD, Blume JD, Weatherall P, et al. Screening women at high risk for breast cancer with mammography and magnetic resonance imaging. Cancer. 2005;103(9):1898–905.

    Article  PubMed  Google Scholar 

  199. Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet. 2005;365(9473):1769–78.

    Article  CAS  PubMed  Google Scholar 

  200. Warner E, Hill K, Causer P, et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. J Clin Oncol. 2011;29(13):1664–9.

    Article  PubMed  PubMed Central  Google Scholar 

  201. Passaperuma K, Warner E, Causer PA, et al. Long-term results of screening with magnetic resonance imaging in women with BRCA mutations. Br J Cancer. 2012;107(1):24–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  202. Berg WA, Blume JD, Cormack JB, et al. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA. 2008;299(18):2151–2163.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  203. Berg WA, Zhang Z, Lehrer D, et al. Detection of breast cancer with addition of annual screening ultrasound or a single screening MRI to mammography in women with elevated breast cancer risk. JAMA. 2012;307(13):1394–404.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  204. Rafferty EA, Park JM, Philpotts LE, et al. Assessing radiologist performance using combined digital mammography and breast tomosynthesis compared with digital mammography alone: results of a multicenter, multireader trial. Radiology. 2013;266(1):104–13.

    Article  PubMed  Google Scholar 

  205. Rhodes DJ, Hruska CB, Phillips SW, Whaley DH, O’Connor MK. Dedicated dual-head gamma imaging for breast cancer screening in women with mammographically dense breasts. Radiology. 2011;258(1):106–18.

    Article  PubMed  Google Scholar 

  206. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975–2009 (vintage 2009 populations). National Cancer Institute; 2012. http://seer.cancer.gov/csr/1975_2009_pops09/. Accessed 28 Nov 2016.

  207. Lalloo F, Varley J, Moran A, et al. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer. 2006;42(8):1143–50.

    Article  CAS  PubMed  Google Scholar 

  208. Fu R, Harris EL, Helfand M, Nelson HD. Estimating risk of breast cancer in carriers of BRCA1 and BRCA2 mutations: a meta-analytic approach. Stat Med. 2007;26(8):1775–87.

    Article  PubMed  Google Scholar 

  209. Freisinger F, Domchek SM. Clinical implications of low-penetrance breast cancer susceptibility alleles. Curr Oncol Rep. 2009;11(1):8–14.

    Article  CAS  PubMed  Google Scholar 

  210. Mavaddat N, Pharoah PD, Blows F, et al. Familial relative risks for breast cancer by pathological subtype: a population-based cohort study. Breast Cancer Res. 2010;12(1):R10.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  211. Phipps AI, Li CI, Kerlikowske K, Barlow WE, Buist DS. Risk factors for ductal, lobular, and mixed ductal-lobular breast cancer in a screening population. Cancer Epidemiol Biomark Prev. 2010;19(6):1643–54.

    Article  Google Scholar 

  212. Welsh ML, Buist DS, Aiello Bowles EJ, Anderson ML, Elmore JG, Li CI. Population-based estimates of the relation between breast cancer risk, tumor subtype, and family history. Breast Cancer Res Treat. 2009;114(3):549–58.

    Article  PubMed  Google Scholar 

  213. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007;447(7148):1087–93.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  214. De Bruin ML, Sparidans J, van’t Veer MB, et al. Breast cancer risk in female survivors of Hodgkin’s lymphoma: lower risk after smaller radiation volumes. J Clin Oncol. 2009;27(26):4239–46.

    Article  PubMed  Google Scholar 

  215. McKian KP, Reynolds CA, Visscher DW, et al. Novel breast tissue feature strongly associated with risk of breast cancer. J Clin Oncol. 2009;27(35):5893–8.

    Article  PubMed  PubMed Central  Google Scholar 

  216. Santen RJ, Mansel R. Benign breast disorders. N Engl J Med. 2005;353(3):275–85.

    Article  CAS  PubMed  Google Scholar 

  217. Bodian CA, Perzin KH, Lattes R. Lobular neoplasia. Long term risk of breast cancer and relation to other factors. Cancer. 1996;78(5):1024–34.

    Article  CAS  PubMed  Google Scholar 

  218. Zhou WB, Xue DQ, Liu XA, Ding Q, Wang S. The influence of family history and histological stratification on breast cancer risk in women with benign breast disease: a meta-analysis. J Cancer Res Clin Oncol. 2011;137(7):1053–60.

    Article  PubMed  PubMed Central  Google Scholar 

  219. Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR. Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. JAMA. 1996;276(17):1404–8.

    Article  CAS  PubMed  Google Scholar 

  220. Kotsopoulos J, Chen WY, Gates MA, Tworoger SS, Hankinson SE, Rosner BA. Risk factors for ductal and lobular breast cancer: results from the nurses’ health study. Breast Cancer Res. 2010;12(6):R106.

    Article  PubMed  PubMed Central  Google Scholar 

  221. Gunter MJ, Hoover DR, Yu H, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 2009;101(1):48–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  222. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–333.

    Article  CAS  PubMed  Google Scholar 

  223. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA. 2002;288(1):58–66.

    Article  CAS  PubMed  Google Scholar 

  224. Beral V, Reeves G, Bull D, Green J. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst. 2011;103(4):296–305.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  225. Hankinson SE. Endogenous hormones and risk of breast cancer in postmenopausal women. Breast Dis. 2005;24:3–15.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Kelly K. Hunt MD

  2. Johns Hopkins University, Baltimore, MD, USA

    David M. Euhus MD

  3. Mayo Clinic, Rochester, MN, USA

    Judy C. Boughey MD

  4. Yale University, New Haven, CT, USA

    Anees B. Chagpar MD

  5. Columbia University, New York, NY, USA

    Sheldon M. Feldman MD

  6. Northwestern University, Chicago, IL, USA

    Nora M. Hansen MD & Swati A. Kulkarni MD

  7. University of Toronto, Toronto, ON, Canada

    David R. McCready MD

  8. Orlando Health, Orlando, FL, USA

    Eleftherios P. Mamounas MD

  9. University of Wisconsin, Madison, WI, USA

    Lee G. Wilke MD

  10. Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Kimberly J. Van Zee MD & Monica Morrow MD

Authors
  1. Kelly K. Hunt MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David M. Euhus MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Judy C. Boughey MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anees B. Chagpar MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sheldon M. Feldman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Nora M. Hansen MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Swati A. Kulkarni MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. David R. McCready MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Eleftherios P. Mamounas MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Lee G. Wilke MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Kimberly J. Van Zee MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Monica Morrow MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kelly K. Hunt MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hunt, K.K., Euhus, D.M., Boughey, J.C. et al. Society of Surgical Oncology Breast Disease Working Group Statement on Prophylactic (Risk-Reducing) Mastectomy. Ann Surg Oncol 24, 375–397 (2017). https://doi.org/10.1245/s10434-016-5688-z

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1245/s10434-016-5688-z

Keywords

Search

Navigation